Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.

3 Nov 2010

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.

2 Nov 2010

Health Canada approves PRADAX for preventing stroke in AF patients

Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate, marking the second approval of this new oral anticoagulant following the recent marketing authorisation by the US Food and Drug Administration (FDA).

30 Oct 2010

Coherex achieves two milestones in structural heart disease field

In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.

29 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.

26 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

UC San Diego researchers receive two federal grants for biomedical informatics

Researchers at the University of California, San Diego School of Medicine, led by Lucila Ohno-Machado, MD, PhD, chief of the Division of Biomedical Informatics in the Department of Medicine, have received two federal grants totaling more than $25 million to develop new ways to gather, analyze, use and share vast, ever-increasing amounts of biomedical information.

25 Oct 2010

New guidelines feature various key updates for stroke or TIA survivors

Treating metabolic syndrome and undergoing carotid angioplasty may prevent recurrent stroke or transient ischemic attack, according to revised American Heart Association/American Stroke Association guidelines.

22 Oct 2010

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.

20 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

Health IT may bring unintended consequences

The Philadelphia Inquirer: As the Obama administration nudges the health system toward electronic medical records, researchers have identified some unintended consequences.

6 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Research Roundups: Racial Disparities at end of life; stopping medicine mistakes; Grand Junction, Colorado's Cost Lessons

Racial Disparities In The Outcomes Of Communication On Medical Care Received Near Death Black patients receive more life prolonging measures and less comfort-directed care at the end of life (EOL) than white patients, such as increased rates of resuscitation, intensive care unit hospitalization, and feeding tube use at the EOL, write the authors of this study that examined whether differences in patient-physician communication contribute to these differences.

4 Oct 2010

Researchers study gene interactions for personalized drug prescriptions

The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.

1 Oct 2010

Computer-assisted decisions can sometimes cause problems for prescribing

Experts hoped computers could help doctors make treatment safer for patients, but it turns out they have side effects, too. The Wall Street Journal's Health Blog reports, for one study,the anti-clotting drug warfarin and a certain antibiotic can produce hazardous effects when taken together.

29 Sep 2010

Warfarin News and Research

Further Reading

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Health Canada approves PRADAX for preventing stroke in AF patients

Coherex achieves two milestones in structural heart disease field

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Aspirin reduces risk of death from prostate cancer

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

UC San Diego researchers receive two federal grants for biomedical informatics

New guidelines feature various key updates for stroke or TIA survivors

FDA approves Boehringer Ingelheim's Pradaxa for stroke risk reduction in patients with non-valvular AF

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Health IT may bring unintended consequences

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Research Roundups: Racial Disparities at end of life; stopping medicine mistakes; Grand Junction, Colorado's Cost Lessons

Researchers study gene interactions for personalized drug prescriptions

Computer-assisted decisions can sometimes cause problems for prescribing

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News